Gepotidacin for the Treatment of Uncomplicated Urogenital Gonorrhea: A Phase 2, Randomized, Dose-Ranging, Single-Oral Dose Evaluation | Zendy

Stephanie N. Taylor | Zendy; David H. Morris | Zendy; Ann Avery | Zendy; Kimberly Workowski | Zendy; Byron E. Batteiger | Zendy; Courtney Tiffany | Zendy; Caroline Perry | Zendy; Aparna Raychaudhuri | Zendy; Nicole E. Scangarella-Oman | Zendy; Mohammad Hossain | Zendy; Étienne Dumont | Zendy

Open Access

Gepotidacin for the Treatment of Uncomplicated Urogenital Gonorrhea: A Phase 2, Randomized, Dose-Ranging, Single-Oral Dose Evaluation

Author(s) -

Stephanie N. Taylor,

David H. Morris,

Ann Avery,

Kimberly Workowski,

Byron E. Batteiger,

Courtney Tiffany,

Caroline Perry,

Aparna Raychaudhuri,

Nicole E. Scangarella-Oman,

Mohammad Hossain,

Étienne Dumont

Publication year - 2018

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciy145

Subject(s) - gonorrhea , medicine , genitourinary system , neisseria gonorrhoeae , adverse effect , population , confidence interval , gastroenterology , microbiology and biotechnology , immunology , biology , environmental health , human immunodeficiency virus (hiv)

In this phase 2 study, we evaluated the efficacy and safety of oral gepotidacin, a novel triazaacenaphthylene bacterial type II topoisomerase inhibitor, for the treatment of uncomplicated urogenital gonorrhea.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research